NCI Dictionary of Cancer Terms
The search textbox has an autosuggest feature. When you enter three or more characters, a list of up to 10 suggestions will popup under the textbox. Use the arrow keys to move through the suggestions. To select a suggestion, hit the enter key. Using the escape key closes the listbox and puts you back at the textbox. The radio buttons allow you to toggle between having all search items start with or contain the text you entered in the search box.
anti-VEGFR-2 fully human monoclonal antibody IMC-1121B (AN-tee … ful-ee HYOO-mun MAH-noh-KLOH-nul AN-tee-BAH-dee …)
A drug used to treat cancer of the stomach or gastroesophageal junction (area where the esophagus connects to the stomach) that is advanced or has spread to other parts of the body. It is used in patients whose cancer has gotten worse after treatment with other anticancer drugs. It is also being studied in the treatment of other types of cancer. Anti-VEGFR-2 fully human monoclonal antibody IMC-1121B binds to receptors for a protein called vascular endothelial growth factor (VEGF), which may be found on some types of cancer cells. This may prevent the growth of new blood vessels that tumors need to grow. Anti-VEGFR-2 fully human monoclonal antibody IMC-1121B is a type of antiangiogenesis agent and a type of monoclonal antibody. Also called Cyramza, IMC-1121B, and ramucirumab.